Success Metrics

Completion Rate
0%(0/2)
Active Trials
0(0%)
Terminated
2(13%)

Phase Distribution

Ph phase_1
11
73%
Ph phase_2
4
27%

Phase Distribution

11

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution15 total trials
Phase 1Safety & dosage
11(73.3%)
Phase 2Efficacy & side effects
4(26.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 15 finished

Non-Completion Rate

100.0%

15 ended early

Currently Active

0

trials recruiting

Total Trials

15

all time

Status Distribution
Terminated(15)

Detailed Status

Withdrawn13
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
15
Active
0
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 111 (73.3%)
Phase 24 (26.7%)

Trials by Status

withdrawn1387%
terminated213%

Recent Activity

Clinical Trials (15)

Showing 15 of 15 trials
NCT03169764Phase 1

QUILT-3.047: NANT Head and Neck Squamous Cell Carcinoma (HNSCC) Vaccine: Combination Immunotherapy in Subjects With HNSCC Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03169790Phase 1

QUILT-3.052: NANT Non-Hodgkin Lymphoma (NHL) Vaccine: Combination Immunotherapy in Subjects With Relapsed CD20-positive NHL

Withdrawn
NCT03647423Phase 1

QUILT-3.091 NANT Chordoma Vaccine vs Radiation in Subjects With Unresectable Chordoma.

Withdrawn
NCT03167164Phase 1

QUILT-3.045: NANT Merkel Cell Carcinoma (MCC) Vaccine: Combination Immunotherapy in Subjects With MCC Who Have Progressed on or After PD-L1 Therapy

Withdrawn
NCT03574649Phase 2

QUILT-2.024: Phase 2 Neoadjuvant, Consolidation, and Adjuvant Combination NANT Immunotherapy Versus Standard of Care in Subjects With Resectable Non-small Cell Lung Cancer

Withdrawn
NCT03167177Phase 1

QUILT-3.046: NANT Melanoma Vaccine: Combination Immunotherapy in Subjects With Melanoma Who Have Progressed On or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03554109Phase 2

QUILT-3.057: NANT Neoadjuvant Triple- Negative Breast Cancer (TNBC) Vaccine

Withdrawn
NCT03197571Phase 1

QUILT-3.048: NANT Urothelial Cancer Vaccine: Combination Immunotherapy in Subjects With Urothelial Cancer Who Have Progressed on or After Chemotherapy and PD-1/PD-L1 Therapy

Withdrawn
NCT03563144Phase 2

QUILT-3.088: NANT Pancreatic Cancer Vaccine

Withdrawn
NCT03197584Phase 1

QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With Epithelial Ovarian Cancer Who Have Progressed on or After Standard-of-care (SoC) Therapy

Withdrawn
NCT03169777Phase 1

QUILT-3.050: NANT Colorectal Cancer (CRC) Vaccine: Combination Immunotherapy in Subjects With Recurrent or Metastatic CRC

Withdrawn
NCT03169738Phase 1

QUILT-3.044: NANT Non-small Cell Lung Cancer (NSCLC) Vaccine: Combination Immunotherapy in Subjects With NSCLC Who Have Progressed After Treatment With PD-1/PD-L1 Inhibitors

Withdrawn
NCT03175666Phase 1

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Withdrawn
NCT03563157Phase 1

QUILT 3.071: NANT Colorectal Cancer (CRC) Vaccine

Terminated
NCT03853317Phase 2

QUILT-3.063: A Study of N-803, haNK and Avelumab in Patients With Merkel Cell Carcinoma That Has Progressed After Checkpoint Therapy

Terminated

All 15 trials loaded

Drug Details

Intervention Type
BIOLOGICAL
Total Trials
15